Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05069428 · ClinicalTrials.gov registry record · Phase 4
Delirium Reduction With Ramelteon
A Phase 4 study of Delirium, sponsored by Centennial Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 506
- Enrollment target
- 1
- Study location
NCT05069428 is a Phase 4 study of Delirium that is actively recruiting participants, run by Centennial Medical Center. The registered enrollment target is 506 participants, below the 879-participant average among 62 other Delirium trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05069428, a Phase 4 study of Delirium, is actively recruiting participants, sponsored by Centennial Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 506 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall purpose of this study is to identify a medication that might treat and/or prevent delirium in intensive care unit (ICU). Currently, there is no proven medical therapy for prevention or treatment of delirium. Ramelteon is a medication approved for insomnia. We hypothesize that ramelteon may help regulate the day/night cycle and decrease ICU delirium.
Conditions Studied
Interventions
- DRUG Ramelteon 8mg
Study Locations (1)
Tennessee
- Centennial Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2023-03-26 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05069428
The ClinicalTrials.gov registry entry for NCT05069428 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 506 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 879-participant average among 62 other Delirium trials with a reported enrollment target (42% lower). The listed sponsor is Centennial Medical Center, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Delirium appearing as the primary indexed condition, and to 1 intervention - of which Ramelteon 8mg is the first listed.
NCT05069428 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT05069428 about?
NCT05069428 is a clinical study titled "Delirium Reduction With Ramelteon". The overall purpose of this study is to identify a medication that might treat and/or prevent delirium in intensive care unit (ICU). Currently, there is no proven medical therapy for prevention or treatment of delirium. Ramelteon is a medication approved for insomnia. We hypothesize that ramelteon m...
What is the current status of trial NCT05069428?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 506 participants. The study started on 2023-03-26. Estimated completion is 2025-12.
What conditions does trial NCT05069428 study?
This clinical trial studies the following conditions: Delirium.
What interventions are being tested in trial NCT05069428?
The interventions under investigation include: Ramelteon 8mg (DRUG).
Who is sponsoring clinical trial NCT05069428?
This trial is sponsored by Centennial Medical Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05069428 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Delirium
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
COMPLETED · Phase 4
-
Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?
COMPLETED · Phase 4
-
Researching Efficient Approaches to Delirium Identification-Sustaining Effective Translation
RECRUITING · NA
-
VoiceLove Digital Therapy for Delirium in the ICU
RECRUITING · NA
-
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
RECRUITING · NA
-
TaVNS for Delirium
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.